Successful achievement of sustained virological response to triple combination therapy containing simeprevir in two patients with chronic hepatitis C who had failed asunaprevir:Daclatasvir combination therapy

2016 ◽  
Vol 46 (11) ◽  
pp. 1162-1167 ◽  
Author(s):  
Itaru Ozeki ◽  
Tomoaki Nakajima ◽  
Masakatsu Yamaguchi ◽  
Mutsuumi Kimura ◽  
Tomohiro Arakawa ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Sustained Virological Response ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Triple Combination ◽  
Triple Combination Therapy

scholarly journals Evolution of Interferon-Based Therapy for Chronic Hepatitis C

2010 ◽  
Vol 2010 ◽  
pp. 1-12 ◽  
Author(s):  
Chun-Hao Chen ◽  
Ming-Lung Yu
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Standard Of Care ◽  
Rapid Virological Response ◽  
Current Standard ◽  
Sustained Response Rate ◽  
Triple Combination Therapy

Since 1986, interferon-alfa (IFN-) monotherapy has been administered for patients with chronic hepatitis C (CHC). However, sustained response rate is only about 8% to 9%. Subsequent introduction of ribavirin in combination with IFN- was a major breakthrough in the treatment of CHC. Sustained virological responses (SVRs) rate is about 30% in hepatitis C virus genotype 1 (HCV-1) patients, and is about 65% in HCV-2 or -3 patients. After 2000, pegylated interferon (PegIFN) much improved the rates of SVR. Presently, PegIFN--ribavirin combination therapy has been current standard of care for patients infected with HCV. In patients with HCV-1, treatment for 48 weeks is optimal, but 24 weeks of treatment is sufficient in HCV-2 or -3 infected patients. Clinical factors have been identified as predictors for the efficacy of the IFN-based therapy. The baseline factor most strongly predictive of an SVR is the presence of HCV-2 or -3 infections. Rapid virological response (RVR) is the single best predictor of an SVR to PegIFN-ribavirin therapy. If patients can't achieve a RVR but achieve a complete early virological response (cEVR), treatment with current standard of care can provide more than 90% SVR rate. HCV-1 patients who do not achieve an EVR should discontinue the therapy. Recent advances of protease inhibitor may contribute the development of a novel triple combination therapy.

Sign in / Sign up

Export Citation Format

Share Document